Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide.
$155.11+2.84%
报价 2026-11-06
市值
$17.31B
EV
$19.24B
PE (TTM)
72.2x
预期 PE (FY2026)
28.6x
52 周区间距高点 -6.4%
$82.26$165.78
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 5.55 → 5.96（1.1x） | 26.0 |
| FY+32028-12 | 1.1x | 5.55 → 6.54（1.2x） | 23.7 |
毛利率 52% · TTM 收入 $2942M · 基数 EPS 5.55（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RVTYRevvity, Inc. | $17.31B | +2.8% | +0.6% | 57.1% | 72.2x | 25.1x | 30.3x | |
| GHGuardant Health, Inc. | $20.25B | -1.7% | +39.5% | 65.4% | – | – | – | 高增长 |
| CRLCharles River Laboratories International, Inc. | $16.17B | +7.8% | -2.2% | 36.2% | – | 91.3x | 46.6x | |
| SOLVSolventum Corporation | $15.38B | +3.7% | -0.7% | 53.5% | 7.3x | 5.5x | – | |
| ICLRICON Public Limited Company | $15.34B | +1.5% | +1.6% | 19.6% | 34.7x | 13.4x | 12.2x | |
| RDYDr. Reddy's Laboratories Limited | $12.42B | +2.6% | – | 55.2% | 18.5x | 12.5x | – | |
| ALGNAlign Technology, Inc. | $11.79B | +4.2% | +2.7% | 68.7% | 24.1x | 14.5x | 16.7x | |
| ENSGThe Ensign Group, Inc. | $10.56B | -0.7% | +16.7% | 16.6% | 26.4x | 19.5x | 24.1x | |
| QGENQiagen N.V. | $10.39B | -1.0% | +2.8% | 63.6% | 25.8x | 16.0x | 23.2x | |
| 同行中位数 | – | – | +2.7% | 54.3% | 25.0x | 14.5x | 23.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-07-05 Q2 2026 | 2026-04-05 Q1 2026 | 2025-12-28 Q4 2025 | 2025-09-28 Q3 2025 | 2025-06-29 Q2 2025 | 2025-03-30 Q1 2025 | 2024-12-29 Q4 2024 | 2024-09-29 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $729.7M | $711.1M | $772.1M | $698.9M | $720.3M | $664.8M | $729.4M | $684M |
| Gross Margin | 57.1% | 54.5% | 43.8% | 53.6% | 54.5% | 56.5% | 49.3% | 56.3% |
| Operating Margin | 12.2% | 10.7% | 14.5% | 11.7% | 12.6% | 10.9% | 18.1% | 15% |
| Net Income | $51.8M | $40.7M | $98.4M | $46.7M | $55.2M | $42.2M | $95M | $94M |
| Diluted EPS | 0.47 | 0.36 | 0.87 | 0.4 | 0.47 | 0.34 | 0.78 | 0.76 |
| Operating Cash Flow | $191.9M | $115.1M | $183.3M | $138.6M | $134.3M | $128.2M | – | $147.9M |